EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy-Reference-Cited by-同舟云学术

EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy

Published:2022-10 Issue:5 Volume:5 Page:530-536
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Fanti Stefano,Briganti Alberto,Emmett Louise,Fizazi Karim,Gillessen Silke,Goffin Karolien,Hadaschik Boris A.,Herrmann Ken,Kunikowska Jolanta,Maurer Tobias,MacLennan Steven,Mottet Nicolas,Murphy Declan G.,Oprea-Lager Daniela E.,O'Sullivan Joe M.,Oyen Wim J.G.,Rouvière Olivier,Sartor Oliver,Stenzl Arnulf,Van Poppel Hendrik,Walz Jochen,Witjes Wim,Bjartell Anders

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference15 articles.

1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer;Mottet,2022

2. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study;Hofman;Lancet,2020

3. 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0;Fendler;Eur J Nucl Med Mol Imaging,2017

4. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients;Rahbar;J Nucl Med,2017

5. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet,2021

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differences and Common Ground in¹⁷⁷Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers;Journal of Nuclear Medicine;2024-01-18

2. PSMA PET/CT Versus mpMRI for the Detection of Clinically Significant Prostate Cancer: An Updated Overview;Seminars in Nuclear Medicine;2024-01

3. Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study;Therapeutic Advances in Medical Oncology;2024-01

4. The Role of Multiparametric MRI and MRI–targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial;European Urology;2024-01

5. The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2023-11-08